163267-87-6

Basic information

• Product Name: [1-(3,3-Diphenylpropyl)-4-piperidinyl]carbamic acid, 1,1-dimethylethyl ester
• Synonyms: [1-(3,3-Diphenylpropyl)-4-piperidinyl]carbamic acid, 1,1-dimethylethyl ester
• CAS NO: 163267-87-6
• Molecular Weight: 394.557
• Mol File: 163267-87-6.mol

Chemical Properties

• CAS DataBase Reference: [1-(3,3-Diphenylpropyl)-4-piperidinyl]carbamic acid, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(3,3-Diphenylpropyl)-4-piperidinyl]carbamic acid, 1,1-dimethylethyl ester(163267-87-6)
• EPA Substance Registry System: [1-(3,3-Diphenylpropyl)-4-piperidinyl]carbamic acid, 1,1-dimethylethyl ester(163267-87-6)

Safety Data

• Hazardous Substances Data: 163267-87-6(Hazardous Substances Data)

Upstream product

• 311-28-4 tetra-(n-butyl)ammonium iodide 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 20017-68-9 1-bromo-3,3-diphenylpropane 

Downstream Products

• 163268-13-1 4-amino-1-(3,3-diphenylpropyl)piperidine 
• 374725-52-7 N-[1-(3,3-diphenylpropyl)-4-piperidinyl]-N-methyl-4-methoxycarbonylphenylacetamide 

Relevant articles and documents

USE OF PIPERIDINE DERIVATIVES AS AGONISTS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to novel piperidinc derivatives and to the use of piperidine derivatives of formula (I) as agonists of chemokine receptor activity.

Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas

Investigation of weak screening hits led to the identification of N-alkyl-N-[1-(3,3-diphenylpropyl)piperidin-4-yl]-2-phenylacetamides and N-alkyl-N-[1-(3,3-diphenylpropyl)piperidin-4-yl]-N′-benzylureas as potent, selective ligands for the human CCR5 chemokine receptor. Investigation of weak screening hits led to the identification of N-alkyl-N-[1-(3,3-diphenylpropyl) piperidin-4-yl]-2-phenylacetamides and N-alkyl-N-[1-(3,3-diphenylpropyl) piperidin-4-yl]-N′-benzylureas as potent, selective ligands for the human CCR5 chemokine receptor.

Ccr5 modulators benzimidazoles or benzotriazoles

The invention concerns compounds of formula (I), wherein the variables are defined herein; processes for preparing them, compositions comprising them and their use in modulating CCR5 receptor activity.

Inhibitors of microsomal triglyceride transfer protein and method

Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure STR1 wherein R1 to R7, Q, X and Y are as defined herein.

Nucleic acids encoding microsomal trigyceride transfer protein

Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.